News is not what we would hope, but there is still a few days before Christmas;-) At least if we get some US investment dollars to move our way this will continue to strengthen the company.
-Dick
RESPONSE BIOMEDICAL CORP.
8855 Northbrook Court
Burnaby, British Columbia
Canada V5J 5J1
Canadian Venture Exchange: RBM
INVESTOR ADVISORY
HARD MONEY ON RESPONSE BIOMEDICAL
Vancouver, British Columbia, December 17, 2001. Response Biomedical Corp.
(RBM: CDNX) developer of the RAMP* diagnostic system, advises that Mr. Jay
Taylor, of Taylor Hard Money Advisors, Inc., has initiated coverage of the
Company.
Mr. Taylor concludes, "... the upside potential for companies providing
solutions to serious problems, by the use of proprietary technologies can be
extremely great. In our view, the risk/reward tradeoff for RBM is highly
favorable for speculative investors who buy the stock at current price
levels and who can afford to tie up their capital indefinitely into the
future."
Based in New York, Mr. Taylor is author of J. Taylor's Gold & Technology
Stocks, a stock market newsletter that covers resource and technology stocks
with significant price appreciation potential. Further information is
available at miningstocks.com.
About Response Biomedical Corp.
Response Biomedical develops quantitative, diagnostic tests for use with its
proprietary RAMP Reader intended to be used for clinical, STAT-lab and
point-of-care applications. The RAMP System is expected to reduce the cost
of healthcare by allowing rapid and easy-to-use medical tests to be
performed in hospitals, clinics, laboratories and physicians' offices
worldwide. The Company's platform technology has the potential to be used
with more than 250 medical and non-medical tests that are currently
performed in laboratories including detection of biological materials used
in bioterrorism. Response Biomedical's shares are listed on the Canadian
Venture Exchange under the trading symbol "RBM". For further information,
visit the Company's website at responsebio.com.
The Canadian Venture Exchange has not reviewed and does not accept
responsibility for the adequacy of the content of the information contained
herein. The statements made in this press release may contain certain
forward-looking statements that involve a number of risks and uncertainties.
Actual events or results may differ from the Company's expectations.
Company Contact:
Bill Radvak
President & CEO
Response Biomedical Corp.
Tel (604) 681-4101, Fax (604) 412-9830
Email: bradvak@responsebio.com |
